Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Multiple analyst price target hikes and AI-driven optimism set a bullish tone into Q3 earnings on Nov 4, but elevated expectations and a negative earnings ESP create two-sided risk.
Schrödinger will report Q3 2026 results after market close on Nov 4, 2026, with a call at 4:30 p.m. ET. Consensus expects a loss of $0.66/share on revenue of $46.02M (down 15.3% YoY); the binary outcome versus these estimates is the primary near-term price driver.
Company Press ReleaseKeyBanc raised its target to $32 from $20 (Overweight), TD Cowen to $31 from $20 (Buy), and BMO to $30 from $24 (Outperform), citing AI-driven drug discovery demand, biotech funding optimism, and hosted-contract execution. The cluster of upgrades lifts the fair value estimate ~16% to $25.86 and supports positive near-term sentiment.
Yahoo FinanceZacks reports an Earnings ESP of -19.08% with the Most Accurate Estimate below consensus, suggesting analysts have turned bearish on Q3 prospects and a beat is unlikely. This tempers upside expectations and raises risk of a negative reaction if results disappoint.
Zacks via Yahoo FinanceUBS maintains a Neutral rating with a $21 target, citing limited near-term catalysts and slower uptake of computational drug discovery for Schrödinger's software model. This divergent view caps upside and highlights valuation risk after the recent rally.
Yahoo FinanceSchrödinger co-founded Tectora, a new immunology and inflammation biotech, alongside NEA and RA Capital, which secured $55M in Series A funding. The announcement drove a 7.6% single-day surge on strong volume and reinforces the AI-drug-discovery narrative supporting the stock.
Zacks via Yahoo Finance